Vivoryon Therapeutics schedules its H1 2026 results release and AGM, giving investors a near‑term view of mid‑year performance
Executive summary: Vivoryon Therapeutics N.V. set August 6, 2026 for its H1 2026 financial results release and scheduled its annual general meeting for the end of September 2026. The announcement gives shareholders a concrete timeline for evaluating the company’s mid‑year performance and any updates on its therapeutic pipeline.
Who is involved: Vivoryon Therapeutics N.V. (the reporting company), its executive management, and its shareholders.
Likely next: On August 6, 2026 the company will publish its H1 2026 financial statements; later in September the AGM will convene to vote on ordinary corporate matters.
Vivoryon Therapeutics N.V. announced that it will disclose its half‑year 2026 financial results and business updates on August 6, 2026, and hold its annual general meeting at the end of September 2026. The press release provides the dates but does not disclose any financial figures or forward‑looking guidance. Investors can use the upcoming disclosure to assess the company’s mid‑year progress and pipeline developments.
Timeline
- — Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 (GlobeNewswire)
Analysis — what this means
Likely next events
- August 6, 2026: H1 2026 financial results release
- End September 2026: Annual General Meeting
Sources
Related cases
- BTQ Technologies reports 2026 AGM voting results, confirming shareholder approval of key governance and compensation matters
- Elbit Systems approves routine governance resolutions at its 2026 AGM, reaffirming board and auditor appointments
- Systemair AB invites shareholders to its annual general meeting on 27 August 2026
- Sivers Semiconductors board members complete approved share purchases following June 2026 AGM